Enzo Biochem Inc
NYSE:ENZ
Enzo Biochem Inc
NYSE:ENZ
Price:
1.09 USD
-1.8%
Market Closed
Updated:
May 18, 2024
Enzo Biochem Inc
Income from Continuing Operations
|
Enzo Biochem Inc
Income from Continuing Operations Peer Comparison
Comparables:
DVA
DGX
CVS
CI
LH
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Enzo Biochem Inc
NYSE:ENZ
|
Income from Continuing Operations
-$46.7m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
|
DaVita Inc
NYSE:DVA
|
Income from Continuing Operations
$1.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
9%
|
CAGR 10-Years
2%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Income from Continuing Operations
$870m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
CVS Health Corp
NYSE:CVS
|
Income from Continuing Operations
$7.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Cigna Corp
NYSE:CI
|
Income from Continuing Operations
$3.9B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Income from Continuing Operations
$400.3m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-3%
|
See Also
What is Enzo Biochem Inc's Income from Continuing Operations?
Income from Continuing Operations
-46.7m
USD
-46.7m
USD
Based on the financial report for Jan 31, 2024, Enzo Biochem Inc's Income from Continuing Operations amounts to -46.7m USD.
What is Enzo Biochem Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-12%
-12%
Over the last year, the Income from Continuing Operations growth was -33%. The average annual Income from Continuing Operations growth rates for Enzo Biochem Inc have been -64% over the past three years , -14% over the past five years , and -12% over the past ten years .
You don't have any saved screeners yet
